top of page

The Future of Mental Health & Wellness


The Breakthrough Treatments of Revitalist


Revitalist makes use of cutting edge, evidence-based treatments on the forefront of mental health and pain conditions.

  • IV Ketamine Infusions
  • Ketamine-Assisted Psychotherapy
  • Spravato - Esketamine
  • Intensive Outpatient Programs
  • (TMS) Transcranial Magnetic Stimulation
  • Medication Infusions
  • Vitamin Infusions
noun_burn out_2683218.png


people worldwide suffer

from depression


Americans die from a drug-related overdose every day


people follow through on suicide attempts every year


of all Americans will have a diagnosable mental health condition in their lifetime

Executive Summary

Future-centric treatments for a variety of mood disorders and pain conditions.

•Stifel GMP recent research report dated January 14, 2021 indicated psychedelic-assisted psychotherapy (PAP) clinics have an addressable market opportunity of US $10b-11b in the US alone

•Flagship clinic Revitalistcommenced operations in February 2018

•Expect to build and buy Ketamine clinics globally:

2021 - 7 clinics
2022 - 48 clinics
2023 - 84 clinics


•Future platform for new psychedelic medicine administered in psychedelic-assisted psychotherapy clinics.

•Telemedicine focused on mental health launching mid-2021


Recent Interviews

Recent News Releases

Current Options

Revitalist Solution


Doctors use antidepressants, but up to two thirds aren’t helped by the first medication. Up to a third are ineffective after several attempts at medication.


The medical community is always searching for new pain management options that provide sustained relief without utilizing opioids.

Suicidal Ideation

Current treatments for suicidal ideation include inpatient hospitalization, psychotherapy, and/or antidepressant medications, which take 4-6 weeks to even begin working and oftentimes prove ineffective.

Mental Health

1 in 5 U.S. adults live with mental illness. Estimates by the National Institutes of Mental Health suggest that only half of these people receive treatment.



Low-dose ketamine infusions coupled with comprehensive treatment has shown to be over 70% effective for clients with treatment-resistant conditions.


Revitalist provides treatment in-house, and the effectiveness of ketamine infusions at managing chronic pain oftentimes allows clients to completely wean off current pain medications in collaborations with their providers.

Suicidal Ideation

Repeated low-dose ketamine infusions over a 2-3 week period have been shown to be 70% effective in alleviating suicidal ideations in those suffering from treatment-resistant depression.

Mental Health

Revitalist wants to increase access to quality mental health and pain management options across the country to allow higher quality of life.


Katie Walker.jpg

Kathryn Walker - CEO

Kathryn is a nursing
anesthesiologist who founded Revitalistin 2018. She has provided care and support to thousands receiving ketamine and has an extensive pipeline of Ketamine clinics in the United States.

Bill Walker.jpg

Ryan Karkainan - Chief Medical Officer

William Walker is a medical doctor that has participated in critical areas of medicine for over 30 years. Dr. Walker believes there is a significant need for comprehensive services providing a greater continuity of care and is grateful to be a part of this new development.


Paul Ciullo - CFO

Paul is a 12-year veteran in senior corporate finance and accounting positions for Fortune 500 companies, including General Electric and Xerox

Grant Whitfield.jpg

Grant Whitfield - Chief Operating Officer

Grant Whitfield joins Revitalist as Chief of Operations with twenty years of experience in both public and private companies.  He most recently helped grow a $36MM privately owned company to projected revenues in 2021 of $219MM as a Director of Project Management, having personally managed over $50+MM worth of accounts.

Dan Kriznic.jpg

Dan Kriznic CPA - Financial Advisor

The team created over $1 billion in enterprise value with $700 million in exits, $243 million in M&A transactions, $175 million in financings and 9 public listings

Larry Heinzlmeir.png

Larry Heinzlmeir - Chief Marketing Officer

Larry Heinzlmeir has been involved with six emerging industries public company listings.  He brings over thirty years of executive level experience in sales and marketing with several of the largest publicly traded companies and for-profit higher education sector, namely DeVry and EDMC, with a combined market cap in excess of $8 billion.

bottom of page